EUVIMEDEUVIMED entdecken
Open Access

Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas

Jurik A Mutter iD, Stefan K Alig iD, Mohammad S Esfahani, Eliza M Lauer iD, Jan Mitschke iD, David M Kurtz iD, Julia Kühn iD, Sabine Bleul, Mari Olsen, Chih Long Liu iD, Michael C Jin iD, Charles W Macaulay iD und 15 weitere

Journal of Clinical Oncology · 20.03.2023 · 41 (9) · 1684-1694

DOI: 10.1200/jco.22.00826 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.03.2023. Verfasst von Jurik A Mutter und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Lymphoma, Non-Hodgkin, Supratentorial Neoplasms. Die Arbeit wurde bisher 129-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Clinical outcomes of patients with CNS lymphomas (CNSLs) are remarkably heterogeneous, yet identification of patients at high risk for treatment failure is challenging. Furthermore, CNSL diagnosis often remains unconfirmed because of contraindications for invasive stereotactic biopsies. Therefore, improved biomarkers are needed to better stratify patients into risk groups, predict treatment response, and noninvasively identify CNSL. PATIENTS AND METHODS We explored the value of circulating tumor DNA (ctDNA) for early outcome prediction, measurable residual disease monitoring, and surgery-free CNSL identification by applying ultrasensitive targeted next-generation sequencing to a total of 306 tumor, plasma, and CSF specimens from 136 patients with brain cancers, including 92 patients with CNSL. RESULTS Before therapy, ctDNA was detectable in 78% of plasma and 100% of CSF samples. Patients with positive ctDNA in pretreatment plasma had significantly shorter progression-free survival (PFS, P < .0001, log-rank test) and overall survival (OS, P = .0001, log-rank test). In multivariate analyses including established clinical and radiographic risk factors, pretreatment plasma ctDNA concentrations were independently prognostic of clinical outcomes (PFS HR, 1.4; 95% CI, 1.0 to 1.9; P = .03; OS HR, 1.6; 95% CI, 1.1 to 2.2; P = .006). Moreover, measurable residual disease detection by plasma ctDNA monitoring during treatment identified patients with particularly poor prognosis following curative-intent immunochemotherapy (PFS, P = .0002; OS, P = .004, log-rank test). Finally, we developed a proof-of-principle machine learning approach for biopsy-free CNSL identification from ctDNA, showing sensitivities of 59% (CSF) and 25% (plasma) with high positive predictive value. CONCLUSION We demonstrate robust and ultrasensitive detection of ctDNA at various disease milestones in CNSL. Our findings highlight the role of ctDNA as a noninvasive biomarker and its potential value for personalized risk stratification and treatment guidance in patients with CNSL. [Media: see text]

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNALymphoma, Non-HodgkinSupratentorial NeoplasmsHumansPrognosisRisk AssessmentBrainBiomarkers, TumorMutation

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • University of Freiburg, Faculty of Biology, Freiburg, Germany.
  • Divisions of Oncology and Hematology, Department of Medicine, Stanford University, Stanford, CA.
  • Department of Neurosurgery, Medical Center-University of Freiburg, Freiburg, Germany.
  • Berta-Ottenstein-Programme for Clinician Scientists Medical Center, University of Freiburg, Freiburg, Germany.
  • Department of Neurology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

ORCID-Profile: Jurik A Mutter, Stefan K Alig, Eliza M Lauer, Jan Mitschke, David M Kurtz, Julia Kühn, Chih Long Liu, Michael C Jin, Charles W Macaulay, Nicolas Neidert, Timo Volk, Dieter H Heiland, Jürgen Finke, Julius Wehrle, Peter C Reinacher, Ash A Alizadeh, Florian Scherer

Förderung

  • NCI NIH HHS

Zitieren

APA

Mutter, J. A., Alig, S. K., Esfahani, M. S., Lauer, E. M., Mitschke, J., Kurtz, D. M., Kühn, J., Bleul, S., Olsen, M., Liu, C. L., Jin, M. C., Macaulay, C. W., Neidert, N., Volk, T., Eisenblaetter, M., Rauer, S., Heiland, D. H., Finke, J., Duyster, J., …, & Scherer, F. (2023). Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas. Journal of Clinical Oncology, 41(9), 1684-1694. https://doi.org/10.1200/jco.22.00826

Vancouver

Mutter JA, Alig SK, Esfahani MS, Lauer EM, Mitschke J, Kurtz DM, et al. Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas. Journal of Clinical Oncology. 2023;41(9):1684-1694. doi:10.1200/jco.22.00826

BibTeX
@article{Mutter2023,
  author = {Mutter, Jurik A and Alig, Stefan K and Esfahani, Mohammad S and Lauer, Eliza M and Mitschke, Jan and Kurtz, David M and Kühn, Julia and Bleul, Sabine and Olsen, Mari and Liu, Chih Long and Jin, Michael C and Macaulay, Charles W and Neidert, Nicolas and Volk, Timo and Eisenblaetter, Michel and Rauer, Sebastian and Heiland, Dieter H and Finke, Jürgen and Duyster, Justus and Wehrle, Julius and Prinz, Marco and Illerhaus, Gerald and Reinacher, Peter C and Schorb, Elisabeth and Diehn, Maximilian and Alizadeh, Ash A and Scherer, Florian},
  title = {Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {9},
  pages = {1684--1694},
  doi = {10.1200/jco.22.00826}
}
Kostenlos starten →